Abstract:Abstract Alzheimer's disease (AD), the most common form of dementia among the elderly, is a progressive, degenerative disorder of the brain with a loss of memory and cognition. A defining characteristic of AD is the deposition of amyloid fibrils and neurofibrillary tangles in the brain of afflicted individuals. Biochemically, they are mainly composed of β‐amyloid protein (Aβ) and phosphorylated tau proteins, respectively. There is also a loss of the presynaptic markers of the cholinergic system, such as acetylcholine, in the brain areas related to memory and learning. The biochemical pathways leading to AD are presently unknown and are a subject of intensive study with current theories favoring a hypothesis where Aβ aggregates to toxic forms that induce tau phosphorylation and aggregation. It is believed that this ultimately leads to dysfunction and death of cholinergic neurons, and compensation for this loss had been the primary focus of first generation therapeutic agents. The amyloid and tau hypotheses have lead to a focus on amyloid and tau as therapeutic targets. The current therapeutic goals are to reduce amyloid levels, prevention of amyloid aggregation/toxicity and tau phosphorylation/aggregation. AD has a heterogeneous etiology with a large percentage termed sporadic AD arising from unknown causes and a smaller fraction of early onset familial AD (FAD) caused by mutations in several genes, such as the β‐amyloid precursor protein (APP) and presenilins (PS1, PS2). Other genes, such as apolipoprotein E (APOE), are considered to be risk factors for AD. Several proteins, such as APP, APOE, BACE (β‐amyloid cleaving enzyme), PS1/2, secretases, and tau play important roles in the pathology of AD. Therefore, attempts are being made to develop new inhibitors for BACE, PS‐1 and γ‐secretase for treatment of AD. There is also a significant advancement in understanding the function of cholinesterase (ChE) in the brain and the use of ChE inhibitors in AD. The mechanism of a new generation of acetyl‐ and butyrylChE inhibitors is being studied and tested in human clinical trials for AD. Other strategies, such as vaccination, anti‐inflammatory agents, cholesterol‐lowering agents, anti‐oxidants and hormone therapy, are also being studied for treating or slowing the progression of AD. Developments of early diagnostic tools based on quantitative biochemical markers will be useful to better follow the course of the disease and to evaluate different therapeutic strategies. In the present review, we attempt to critically examine recent trends in AD research from neurochemical to clinical areas. We analyze various neurobiological mechanisms that provide the basis of new targets for AD drug development. These current research efforts should lead to a deeper understanding of the pathobiochemical processes that occur in the AD brain to effectively diagnose and prevent their occurrence. Drug Dev. Res. 56:267–281, 2002. © 2002 Wiley‐Liss, Inc.

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management

Development of Nanomedicines for the Treatment of Alzheimer's Disease: Raison d'être, Strategies, Challenges and Regulatory Aspects

Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development

Nose-to-brain drug delivery for the treatment of Alzheimer’s disease: current advancements and challenges

Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease

Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets

A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease

Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers

Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks

Treating Alzheimer's disease using nanoparticle-mediated drug delivery strategies/systems

Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease

Alzheimer's disease and drug delivery across the blood–brain barrier: approaches and challenges

New advances in brain-targeting nano-drug delivery systems for Alzheimer's disease

Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach

Mechanistic insights and emerging therapeutic stratagems for Alzheimer's disease

Cutting-Edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease

Biomaterials in treatment of Alzheimer's disease

Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease

Current drug targets for Alzheimer's disease treatment

Advances In Alzheimer'S Disease: A Multifaceted Review Of Potential Therapies And Diagnostic Techniques For Early Detection